Categories: News

Aleafia Health Enters Supply Agreement with Cannabis Brand House BLLRDR

Afghani Bullrider

Rare cultivars.
  • Aleafia Health subsidiary Emblem to exclusively distribute BLLRDR products in medical channel
  • Initial launch to feature rare cultivars Afghani Bullrider and Wedding Cake
  • BLLRDR is majority-owned by two-time GRAMMY Award winning producer Noah “40” Shebib and original Emblem co-founder Max Zavet

TORONTO, Dec. 15, 2020 (GLOBE NEWSWIRE) — Aleafia Health Inc.’s (TSX: AH, OTC: ALEAF) (“Aleafia Health” or the “Company”) wholly-owned subsidiary Emblem Cannabis Corporation has entered into a definitive supply agreement with cannabis brand house Robes Cannabis Inc. (dba BLLRDR). The agreement gives the Company the exclusive rights to sell BLLRDR’s portfolio of rare, highly sought-after cannabis cultivars and other products in the Canadian medical cannabis market.

BLLRDR is majority-owned by two-time GRAMMY Award winning producer and OVO co-founder, Noah “40” Shebib, and Emblem co-founder Max Zavet.

Two highly sought-after cannabis cultivars, Wedding Cake, and the brand’s namesake, the elusive Afghani Bullrider, are slated to launch to Emblem patients in January 2021. Both cultivars are carefully curated for their unique cannabinoid and terpene profiles that appeal to medical patients, with Afghani Bullrider often exhibiting myrcene levels of over one per cent by dried flower weight.

“I’ve never seen cannabis as simply another ‘product,’” said Shebib. “It has been quite the journey to get this brand to the market, and it has always been a top priority to ensure there is medical access. We are excited to be collaborating with the Aleafia team to bring these products to patients.”

“Partnering with Noah, Max and the BLLRDR team has allowed us to broaden our medical cannabis portfolio and bring their unique and differentiated cultivars directly to our patients,” said Aleafia Health CEO Geoffrey Benic.

“We are committed to honouring the legacy of all the advocates who gave their energy to ensure cannabis is accessible and available when needed,” said Zavet. “We will continue to challenge ourselves to bring the best quality and variety of products to this market and will work with the team at Aleafia in order to execute our vision.”

Aleafia Health Contact:

Nicholas Bergamini, VP Investor Relations
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com

About Aleafia Health:

Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and in international markets. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.

Aleafia Health owns three significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules and sprays. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.

Innovation, the heart of Aleafia Health’s competitive advantage, has led to the Company maintaining a medical cannabis dataset with over 10 million data points to inform proprietary illness-specific product development and its highly differentiated education platform FoliEdge Academy. The Company is committed to creating sustainable shareholder value; the TSX Venture Exchange named Aleafia the 2019 top performing company prior to its graduation to the TSX.

Forward Looking Information

This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/41ba3c18-bf20-49b0-8959-9c1a10b71f7b

Staff

Recent Posts

Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide

Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to…

2 hours ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing…

2 hours ago

Optinose Announces 1-for-15 Reverse Stock Split

YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company…

2 hours ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage…

2 hours ago

Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development…

2 hours ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or…

2 hours ago